Aging-US
recently published ”
Transforming growth factor beta type 1 (TGF-β) and hypoxia-inducible factor 1 (HIF-1) transcription complex as master regulators of the immunosuppressive protein galectin-9 expression in human cancer and embryonic cells
” which reported that for the first time that in human cancer as well as embryonic cells, the transcription factors hypoxia-inducible factor 1 and activator protein 1 are involved in upregulation of transforming growth factor beta 1 expression, leading to activation of the transcription factor Smad3.
This process triggers upregulation of galectin-9 expression in both malignant and embryonic cells.
Dr. Vadim V. Sumbayev from
The Universities of Kent and Greenwich
and Dr. Elizaveta Fasler-Kan from
The University of Bern
as well as
The University of Basel and University Hospital Basel
said, “Galectin-9 is one of the crucial proteins used by various types of cancer cells to suppress cytotoxic immune responses and thus, escape immune surveillance”
Some cancer cells are capable of secreting this protein, while other cancer cells translocate
galectin-9
onto the surface and use it to impair anti-cancer activities of cytotoxic lymphoid cells such as cytotoxic T lymphocytes and natural killer cells.
When complexed with Tim-3 on the cell surface, galectin-9 induces downstream signalling of differential intensity, depending on the type of human myeloid and lymphoid cells.
Human
cancer cells
express significantly higher levels of galectin-9 compared to healthy human cells.
Here the
Aging-US
authors report for the first time that in human
breast cancer
, AML and embryonic cells, HIF-1 and AP-1 upregulate the expression of TGF-β, leading to the activation of Smad3 through autocrine action.
This process subsequently upregulates galectin-9 expression in both malignant and embryonic cells, but not in mature healthy human cells.
The Sumbayev/Fasler-Kan Research Team concluded in their
Aging-US
Research Paper
,
“These finding demonstrate a self-supporting mechanism of galectin-9 expression operated by human AML, breast and colorectal cancer as well as embryonic cells. Our results suggest the possibility of using TGF-β signalling as a potential highly efficient target for cancer immunotherapy.”
“The Aging-US authors report for the first time that in human breast cancer, AML and embryonic cells, HIF-1 and AP-1 upregulate the expression of TGF-β”
###
Full Text –
https:/
/
www.
aging-us.
com/
article/
202343/
text
Correspondence to: Vadim V. Sumbayev email:
V.Sumbayev@kent.ac.uk
and Elizaveta Fasler-Kan email:
elizaveta.fasler@insel.ch
Keywords:
galectin-9
,
immune escape
,
TGF-beta
,
HIF-1
About
Aging-US
Launched in 2009,
Aging-US
publishes papers of general interest and biological significance in all fields of aging research as well as topics beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, cancer, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR among others), and approaches to modulating these signaling pathways.
To learn more about
Aging-US
, please visit
http://www.
Aging-US.
com
or connect with
@AgingJrnl
Aging-US
is published by Impact Journals, LLC please visit
http://www.
ImpactJournals.
com
or connect with @ImpactJrnls
Media Contact
18009220957×105
MEDIA@IMPACTJOURNALS.COM
This part of information is sourced from https://www.eurekalert.org/pub_releases/2021-01/ijl-agf012121.php
